Weight-loss medicines in India: what they are, what the trials show, and what they ask of your diet

These are prescription medicines. Whether one is right for a particular person is a medical decision, made by a doctor who knows that person's history, their other conditions and their other medicines. No article can make that decision, and this one does not try. NNWA does not prescribe. A nutrition qualification does not qualify anyone to advise on drug treatment.

This article is general education, not personal advice. Anyone with a medical condition, on any medication, or who is pregnant should work with their own doctor and dietitian. Nothing here names a dose, recommends starting a medicine, or recommends stopping one. If you are already on one of these, prescribed properly, nothing on this page should make you doubt your doctor.

How a weight loss medicine actually works

The drugs people mean when they say weight loss medicine are, at the moment, mostly one family. They are called GLP-1 receptor agonists. Semaglutide is one. It is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. There is also a related drug, tirzepatide, sold as Mounjaro, which acts on two receptors rather than one.

GLP-1 stands for glucagon-like peptide-1. It is a hormone your own gut already makes. Cells in the intestine release it after you eat. In a review of how the hormone works, Daniel Drucker sets out its main jobs: it increases insulin release and reduces glucagon release around a meal, it slows the rate at which the stomach empties, and it reduces food intake. Those last two are the ones that matter for body weight. Food sits in the stomach longer, so fullness lasts longer. Signals reaching appetite centres in the brain change, so the drive to eat falls.

A GLP-1 receptor agonist is a manufactured molecule that fits the same receptor and does the same things, but lasts far longer in the body than the natural hormone does. Tirzepatide goes one step further. The trial report describes it as a molecule that activates both the GIP receptor and the GLP-1 receptor. GIP is another gut hormone released after eating.

The order in which this happened matters, because it explains a lot. These drugs were developed for type 2 diabetes. Blood sugar control was the target. Weight loss was noticed along the way, was larger than anyone expected, and was then studied properly in people who did not have diabetes. That is why the same molecule appears under one brand name for diabetes and another for weight, and why the diabetes brand keeps turning up in conversations about weight.

They are not appetite suppressants in the old sense, and they are not fat burners. They do not make the body spend more energy. They change how hungry a person feels and how quickly they feel full. People then eat less, and the reduced intake is what produces the weight change. That is worth holding on to, because it is exactly why the food side does not go away. If you want the underlying arithmetic, our explainer on the calorie deficit covers it.

What is the difference between Ozempic, Wegovy and Mounjaro?

They are brand names, and the useful distinction is between the molecule inside and the condition the brand is licensed for. Ozempic and Wegovy both contain semaglutide, the same GLP-1 receptor agonist, but they are marketed for different purposes: Ozempic is licensed in India as an addition to diet and exercise for adults with uncontrolled type 2 diabetes, while semaglutide for long-term weight management is sold under the Wegovy name. Mounjaro contains a different molecule, tirzepatide, which the trial report describes as acting on both the GIP and the GLP-1 receptor, and it is approved in India for both type 2 diabetes and long-term weight management. Since semaglutide came off patent in India, a large number of approved generic versions of that molecule are also on the market under other names. This page deliberately does not rank them or suggest that any one is the right choice, because that comparison is a clinical judgement about a specific person and belongs to their doctor.

What the trials actually show

Two large randomised trials are the ones most often quoted, and both were run in people with obesity or overweight who did not have diabetes.

The first is STEP 1, published in the New England Journal of Medicine in 2021. The trial enrolled 1,961 adults and ran for 68 weeks. Participants were randomly assigned to weekly semaglutide injections or to a placebo injection. Average weight change was a fall of 14.9 per cent of body weight in the semaglutide group, against 2.4 per cent in the placebo group. Just over half of the semaglutide group lost at least 15 per cent of their starting weight.

The second is SURMOUNT-1, published in the same journal in 2022. It enrolled 2,539 adults and ran for 72 weeks, testing three different strengths of tirzepatide against placebo. Average weight change across the three treatment groups was a fall of 15.0, 19.5 and 20.9 per cent, rising with the strength used. The placebo group fell 3.1 per cent. In the two higher groups, around half or more of participants lost at least a fifth of their body weight.

Those are real numbers from real trials, and they are much larger than anything diet trials of similar length have produced. Three honest qualifications belong with them, and they are usually left out.

The first is that every one of those figures is an average. Individual results in these trials varied enormously. Some people lost far more than the average. Some lost very little. Nothing in either paper lets a reader predict which they would be. Our piece on how much weight you can realistically lose makes the same point about diet, and it holds here.

The second is that the trials were not drug versus nothing. In STEP 1, both groups received lifestyle intervention alongside the injection. That is why the placebo group lost weight at all, and why nearly a third of placebo participants still lost at least 5 per cent of their body weight. The trial tested the drug added on top of diet and activity support, not the drug on its own. Almost every advertisement and social media clip quoting the headline figure drops this.

The third is that these were trials, with trial conditions. Participants were monitored, followed up and supported. Discontinuation because of stomach and bowel side effects was reported in both papers. Real use outside a trial tends to look less tidy.

How much weight do people lose on these medicines?

In the two big randomised trials, average weight loss at around a year and a half was close to 15 per cent of starting body weight with semaglutide and between 15 and 21 per cent with tirzepatide, depending on the strength used, against roughly 2 to 3 per cent with a placebo injection. Those averages hide very wide individual variation, and both trials gave every participant diet and physical activity support alongside the injection, so the figures describe the drug added to lifestyle change rather than the drug by itself. A reader should also remember that these results were measured while people were still taking the medicine, which is a different question from what happens afterwards. Nobody can tell an individual in advance where in that range they would land, and no article, including this one, should try.

Is Ozempic available in India?

Yes, as at the date this was checked, which was 3 September 2026. Ozempic, the injectable semaglutide brand, was launched in India in December 2025, and it is approved here as an addition to diet and exercise for adults with uncontrolled type 2 diabetes, which is not the same thing as being approved for weight loss. The tirzepatide brand Mounjaro arrived earlier: it was approved by the Central Drugs Standard Control Organisation and launched in India in March 2025, both for glycaemic control in type 2 diabetes and as an addition to diet and exercise for long-term weight management in obesity. Semaglutide for chronic weight management is also marketed in India, and the drug regulator has since approved a further indication for it in liver disease. Every one of these is prescription-only, approvals and brand availability change, and the only reliable way to know what is currently licensed and appropriate is to ask a doctor or a qualified pharmacist rather than a website.

What this costs in India, and why that matters

One more thing changed the Indian picture in 2026. Semaglutide came off patent here, and a group of Indian manufacturers with regulatory approval began selling generic versions, at a range of price points below the originator brands. That has made the drug considerably cheaper than it was at launch, and it has also made the market much more crowded and much harder for an ordinary person to read.

Two things are worth saying about cost, in general terms, because the price is not the interesting part. First, prices differ by brand, by manufacturer and by strength, and they have been moving. Anything a website tells you today may be wrong next quarter. Second, and this is the part that people miss: this is a recurring monthly cost, not a one-time purchase. The trial evidence, which we come to below, points towards these being long-term treatments. Somebody working out whether they can afford this is not comparing it against a one-off expense. They are comparing it against a bill that arrives every month for as long as treatment continues.

Side effects and risks, stated accurately

The common ones are digestive, and they follow directly from the mechanism. If a drug slows the stomach and dulls appetite, the stomach and bowel are where problems show up. Both major trials reported nausea and diarrhoea as the most frequent adverse events with the active drug. A 2026 systematic review of sixteen randomised trials covering 7,096 participants found that these medicines consistently increased nausea, diarrhoea, constipation and vomiting, and that this happened even when people were also getting dietary guidance. The approved product information for semaglutide for weight management lists nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, reflux and hair loss among reactions occurring in at least one person in twenty.

Beyond the common effects, there are rarer and more serious ones, and it is worth being precise about which are established and which are being monitored.

Gallbladder disease is established. A systematic review and meta-analysis of 76 randomised trials covering 103,371 patients found that randomisation to a GLP-1 receptor agonist was associated with a higher risk of gallbladder or biliary disease, including gallstones and gallbladder inflammation, and that the increase was larger in the trials run for weight loss than in the diabetes trials. Rapid weight loss of any kind raises gallstone risk, so some of this is the weight change rather than the molecule. The semaglutide product information carries its own warning about gallstones and gallbladder inflammation.

Pancreatitis is a listed warning. The product information states that acute pancreatitis, including fatal cases, has been seen in people treated with these drugs, and instructs prescribers to stop the medicine if it is suspected.

The thyroid finding is a rodent finding, and it is treated seriously. Semaglutide caused thyroid C-cell tumours in rodents at exposures relevant to human use. This is on the label as a boxed warning. The same label states plainly that whether this applies to humans has not been determined. Regulators have handled the uncertainty by making the drug contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with the genetic syndrome MEN 2. That is the honest position: an animal signal that has not been shown in people, managed by keeping the medicine away from those most likely to be at risk.

Dehydration is the one that connects to food. The label notes that reported cases of acute kidney injury largely occurred in people who became dehydrated through nausea, vomiting or diarrhoea. It also says the drug is not recommended in people with severe gastroparesis, and that there have been rare reports of stomach contents entering the lungs during general anaesthesia. That last point is why anyone on one of these needs to tell a surgeon or anaesthetist before any procedure.

None of that is a reason to avoid these medicines or to take them. It is the information a prescriber weighs, alongside a person's history, before deciding. That decision belongs with the doctor.

What the regain studies found

This is the single most useful thing a reader can know before the subject even comes up, and it is the least reported.

A subset of the STEP 1 participants were followed for a further year after treatment stopped. In that extension, published in 2022, people regained about two-thirds of the weight they had lost. Average loss at the end of treatment was 17.3 per cent of starting weight in the semaglutide group. A year after the drug and the lifestyle programme were withdrawn, the net loss from the original starting point was 5.6 per cent. Improvements in blood pressure, blood lipids and blood sugar markers had largely drifted back towards where they started.

The same pattern showed up in a trial designed to test it directly. In SURMOUNT-4, participants took tirzepatide for 36 weeks and were then randomly assigned either to continue or to switch to placebo. Those switched to placebo regained substantially, while those who continued kept and slightly extended their loss. The authors' conclusion was blunt: withdrawing the drug led to substantial regain of lost weight.

This is not a moral failure and it is not evidence the drugs do not work. It is what you would expect from a treatment that works by changing appetite signalling. Stop the signal, and appetite returns. Blood pressure medicine behaves the same way, and nobody calls that a failure of character. What it does mean, practically, is that these look like long-term treatments rather than a course you complete. Anyone thinking about cost, or about what happens in a year, should be reading these two studies rather than a testimonial. Our page on why weight loss stalls and reverses covers the same biology from the diet side.

What happens when you stop taking them?

Weight comes back, and the studies that looked at this were clear about it. In the STEP 1 extension, participants who came off both the medicine and the lifestyle programme regained about two-thirds of the weight they had lost over the following year, and the improvements in blood pressure, lipids and blood sugar markers drifted back towards where they had started. SURMOUNT-4 tested the same question by design, randomly assigning people who had already lost weight either to continue tirzepatide or to switch to placebo, and those switched to placebo regained substantially while those who continued held on to their loss. This is what you would expect from a treatment that works by changing appetite signalling rather than by permanently changing the body, and it is the reason these are generally described as long-term treatments rather than a course a person finishes. It is also the strongest practical argument for doing the food and activity work properly while the medicine is making it easier, because that work is the only part of the picture that can outlast the prescription.

The counterfeit and grey market problem

Semaglutide and tirzepatide are expensive, in demand, and injectable. That combination attracts counterfeiters, and it has.

The World Health Organization has issued a global alert on falsified semaglutide products. WHO reported falsified batches detected across several countries and rising reports from every world region, and warned that a falsified product may contain none of the active ingredient, or may contain something else entirely, including insulin. An unlabelled insulin dose in someone who does not need insulin is a medical emergency, not an inconvenience. WHO's advice is to obtain these medicines only against a prescription from a licensed doctor, and to avoid buying them from unverified sources.

India has an added complication. Semaglutide came off patent here and a large number of approved manufacturers entered the market at once, which is a legitimate development, but it also means an enormous number of products, packs and names now exist. That noise makes it far easier for something fake to pass unnoticed.

This page will not tell you how to buy these outside the prescription system, will not name a source, and will not describe what a "safe" grey market supply looks like, because there is no such thing. A product bought outside the regulated system carries no assurance of what is inside it, how it was stored, or whether it is sterile. There is no home test a person can do. The only protection available is a prescription from a doctor and a licensed pharmacy.

What these medicines ask of your diet

Here is the part almost nobody writes about, and it is the part a nutrition professional is actually qualified to address.

These drugs work by making people eat less. That is the whole mechanism. When total food intake falls sharply, everything that came in with that food falls too. Protein falls. Iron falls. Calcium falls. Fibre falls. Fluid falls. The weight comes off, and a set of quiet nutritional problems comes with it unless somebody is paying attention. A prescriber writes the prescription. Nobody in that appointment is watching the plate.

Protein falls first, and it matters most

When appetite drops, people do not usually cut evenly across their diet. They cut the things that feel heaviest, and protein foods feel heavy. Meat, fish, eggs, paneer and pulses sit in the stomach. On a drug that already slows the stomach, they are frequently the first things to go.

Protein intake matters more than usual here, not less. A review of muscle during weight loss concluded that a higher protein intake helps preserve lean body and muscle mass while losing weight, and that resistance-type exercise both preserves muscle and improves strength. The honest caveat is that the exact protein requirement for someone on these specific medicines has not been established. The 2026 systematic review of randomised trials said so directly: dietary guidance was commonly given in the trials, but the evidence on the best nutritional approach remains limited, and further work is needed to clarify protein requirements.

For an Indian reader there is an extra wrinkle. A lot of Indian eating is grain-led. Rice, roti, poha, idli and paratha carry the meal, with the protein foods playing a supporting part. That structure is workable at a normal appetite. It falls apart when total capacity shrinks, because grain fills the small space first and there is nothing left for anything else. If protein is new territory, start with our guide to protein for weight loss and the Indian high-protein food list. Vegetarians in particular should look at where Indian vegetarian protein actually comes from, because dal alone does not carry it. The protein calculator will show how the requirement is worked out, but the number that applies to a specific person on a specific medicine is a conversation with a dietitian, not something an article should hand out.

Lean mass, and what the data honestly shows

Fat is not the only tissue that leaves during weight loss. Some lean tissue goes too, and this is true of any method, including diet alone.

The picture with these drugs specifically is genuinely mixed, so here is both halves of it. A systematic review of six studies covering 1,541 adults found that weight reduction with semaglutide came mostly from fat mass, that lean mass held steady in some studies and fell noticeably in others, particularly in the larger trials, and that the proportion of lean mass relative to total body mass went up. The larger and more recent review of sixteen randomised trials reached a more reassuring conclusion, reporting that lean mass was generally preserved with reductions roughly proportional to the total weight lost.

So the alarming version doing the rounds on social media, that these drugs melt muscle, is not what the trial data says. But the trials also gave participants lifestyle support, and "proportional to total weight loss" still means real lean tissue when the total loss is a fifth of body weight. The two levers that are known to protect muscle during weight loss are adequate protein and resistance training, and neither one happens by accident. Somebody has to organise them.

Micronutrients drop with total food volume

Vitamins and minerals arrive inside food. Eat considerably less food, and you get considerably less of them, unless the food that remains is chosen well.

This is not a new problem invented by these drugs. An analysis of menus from three commercial weight-loss plans found several micronutrients falling below recommended amounts across the plans, including vitamin D and calcium. Restriction of any kind squeezes micronutrient intake. What is different here is the degree. A person eating a fraction of their former volume, for a year or more, has very few opportunities left to meet a requirement, and every one of them has to count.

The practical consequence is that food selection matters more when there is less of it, not less. If a diet was already short on iron, calcium or B12 before the medicine, eating half as much of it will not improve matters. This is exactly the reasoning behind the obesity diet guide, and it applies with more force, not less, when a drug is involved.

Nausea, constipation, dehydration and food aversions

These are the day-to-day problems, and they are food problems as much as medical ones. The professional body for dietitians in the United States has set out the role of dietitians alongside these medicines, which it describes as supporting adherence, preventing and managing side effects, supporting adequate nutrient intake, and building eating patterns that survive the treatment. That is a fair description of the job.

In food terms, the usual approach looks like this. Smaller amounts eaten more often, rather than three normal-sized meals that cannot be finished. Very rich, very oily and very heavily spiced food is often poorly tolerated when the stomach is already emptying slowly. Cooler and plainer foods are frequently easier than hot, strongly aromatic ones. Fluids taken between meals rather than with them, so that limited stomach space is not spent on water at the moment food needs to go in.

Constipation needs fibre and fluid together. Fibre added without enough fluid reliably makes constipation worse, and someone who is drinking less because they feel full is already short of fluid. Dehydration is not a minor issue here. The product information links reported cases of kidney injury mainly to people who became dehydrated through nausea, vomiting or diarrhoea. Fluid intake stops being automatic when thirst and appetite both fall, so it has to become deliberate.

Food aversions are the underrated one. People commonly report that specific foods become actively unpleasant, and meat and fried food are frequent casualties. That is tolerable in itself. The problem is that the foods lost are usually protein foods, and the foods that remain acceptable are usually not.

What an Indian plate looks like when capacity is tiny

This is the practical heart of it. Assume someone can only manage a small bowl at a sitting. What goes in it?

Protein goes in first. Not as a side dish, not as an afterthought, but as the first thing on the plate and the first thing eaten. Curd, paneer, egg, fish, chicken, soya chunks and dal are all workable. Curd and egg are particularly useful because they are soft, familiar, cheap and go down easily when other things do not.

The grain shrinks to fit what is left. This is the reverse of how most Indian meals are built, and it feels wrong at first. A meal of two rotis and a little sabzi, or a plate of rice with a thin dal, is a perfectly ordinary Indian meal that becomes a nutritional problem at low volume, because almost all of the small amount eaten is carbohydrate. The same meal with the proportions flipped works far better.

Dal deserves a specific note. Dal is a good food and a cultural staple, but a watery dal is mostly water. If dal is doing the protein work in a vegetarian meal, it needs to be thick, and it needs company from curd, paneer or soya.

The trap is the soft sweet food. This is the most predictable failure of all, and it catches people who are otherwise doing everything right. When solid food is unappealing and the stomach feels full, what still goes down easily is soft, sweet and liquid. Sweet tea. Biscuits. Kheer. Ice cream. Juice. Milkshakes. These slide past a suppressed appetite in a way that a piece of fish does not. Somebody can end up eating very little in total while getting a surprising share of that little from sugar, with almost no protein and almost no micronutrients attached. If a person is going to spend a small appetite, spending it on sweet soft food is the worst available use of it. Our Indian weight loss diet plan is built around this idea of getting the most out of every plate, and it becomes more relevant, not less, when the plate gets smaller. Anyone who also has type 2 diabetes should read this alongside the diabetes diet guide, because the sugar point there is not only about weight.

Eating patterns after the medicine

The regain data from the STEP 1 extension and SURMOUNT-4 is the reason this last part exists. When treatment stops, appetite returns. It returns to a person who may have spent a year or more eating almost nothing, and who may not have built a single new habit in that time, because the drug made habits feel unnecessary.

That is the gap the nutrition work fills. Learning what a balanced plate looks like, learning to cook it, learning to eat it at a normal appetite, and doing that while the drug is still making it easy, is the only thing that gives a person anything to stand on afterwards. It is not a guarantee. The extension study makes clear that appetite biology is powerful and regain is common. But the alternative, which is arriving at the end of treatment with returning hunger and no skills, is not a plan at all.

None of this is a reason to reject the medicines. It is an argument that they are half of a treatment, and that the other half is food, and the other half does not happen unless someone makes it happen.

Do you still need to think about food on a weight loss medicine?

Yes, and arguably more carefully than before, though for different reasons. Before, the food work was mostly about controlling how much a person ate. On one of these medicines the drug is doing that part, and the food work shifts to making sure that what little is eaten actually contains what a body needs: enough protein to protect muscle, enough micronutrients from a much smaller volume, enough fluid and fibre to keep the gut working, and an eating pattern that a person could still follow if the medicine ever stopped. The trials that produced the headline results all included diet and activity support for exactly this reason, and dropping that half of the intervention while keeping the injection is not what was tested. A person can lose a great deal of weight and still end up worse nourished than when they started, and that outcome is entirely preventable with attention to what goes on the plate.

Where a nutrition professional fits, and where they do not

A nutrition professional supports the eating side, alongside the prescriber, and never advises on the drug itself. That boundary is not a formality. If a client is on one of these medicines, the practitioner's job is protein intake, micronutrient adequacy, symptom management in food terms, hydration, fibre, lean mass through resistance work, and the eating pattern that has to outlast the treatment, all in coordination with the doctor who prescribed it. What the practitioner does not do is comment on whether the medicine is right, suggest a change, discuss dosing, or say anything that could be read as encouraging someone to start or stop. Questions of that kind go straight back to the prescriber, every time. A practitioner who is unclear about where that line sits should assume it is closer than they think.

It is worth being direct about qualifications here too. A skill qualification is not a degree. Registered Dietitian status in India needs a BSc or MSc plus registration with the Indian Dietetic Association. A short course, a diploma or a certification builds real and useful skill in nutrition practice, and our Diploma in Nutrition, Dietetics and Public Health is built for that, but it does not make anyone a doctor and it does not make anyone an RD. In clinical situations like this one, the practitioner works with the medical team, not around it.

Can a nutritionist advise a client who is on a weight loss medicine?

Not on the medicine itself, no, and that boundary should be stated to the client out loud rather than assumed. A nutrition professional's remit with someone on one of these drugs is the eating side: protein intake, micronutrient adequacy from a much smaller volume of food, hydration and fibre, managing nausea and constipation in food terms, supporting resistance training to protect lean mass, and building an eating pattern that could survive the treatment ending. Everything to do with the drug itself, including whether it suits the person, whether anything should change, how it is taken, and what to do about a side effect that is not settling, goes back to the prescribing doctor. Practitioners in India should also be clear about their own credentials when they say this, since a skill qualification is not a degree and Registered Dietitian status requires a BSc or MSc plus Indian Dietetic Association registration. Working in coordination with the medical team is not a limitation on the role, it is the role.

Where this leaves you

These are genuine medicines. They work, the trial evidence is strong, and the effect sizes are larger than anything diet trials of the same length have produced. Using one is not a moral question and it is not a shortcut anyone owes an apology for. Obesity is a medical condition with biological, genetic, environmental and medication-related drivers, and treating it with medicine is a reasonable thing for a doctor and a patient to decide together.

They are also not a substitute for knowing how to eat. The trials that produced those numbers included diet and activity support. The regain studies show what happens when the treatment stops. The nutritional problems that come with eating very much less are real, documented and manageable, but only by someone paying attention to them.

The diet question does not disappear when a medicine is involved. It changes shape. It stops being about eating less and starts being about making very little count for a great deal, and about building something that still stands when the appetite comes back.